Michael Ackermann
Presidio Medical

Jason Andrew
Limelight Health

Fabien Beckers
Arterys

Adam Berman
TVA Medical/Alleviant Medical

Russ Branaghan
Research Collective, LLC

Lucas Buchanan
Silk Road Medical

David Cassak
MedTech Strategist

Tony Chou
Silk Road Medical

Andrew Cleeland
Fogarty Institute for Innovation (FII)

Joe Cunningham
Santé Ventures

William Dai
ShangBay Capital

Jeff (J.D.) Davids
SmartMoney Ventures

Ron Dollens
Retired President & CEO, Guidant Corporation

James Eadie
Santé Ventures

Lisa Earnhardt
Abbott

Ian Edvalson
Wilson Sonsini Goodrich & Rosati

Vera Elson
Wilson Sonsini Goodrich & Rosati

Chris Eso
Medtronic

Bryant Foster
Research Collective, LLC

Michael Friedrich
DistalMotion SA

Enhao Gong
Subtle Medical

Ginger Graham
Amylin Pharmaceuticals 

Paul Grand
MedTech Innovator

Joshua Gruenspecht
Wilson Sonsini Goodrich & Rosati

Joel Harris
InCube Labs

Kristen Havranek
Wilson Sonsini Goodrich & Rosati

Matt Heim
Qventus, Inc.

 

James Heslin
Wilson Sonsini Goodrich & Rosati

Steve Hochberg
Deerfield Ventures

David Hoffmeister
Wilson Sonsini Goodrich & Rosati

Scott Huennekens
Formally Verb Surgical

James Huie
Wilson Sonsini Goodrich & Rosati

Beverly Huss
Qool Therapeutics

Mir Imran
Rani Therapeutics LLC/InCube
Labs LLC

Tomoko Ishikura
Nipro Medical Corporation

Jim Jenson
Wilson Sonsini Goodrich & Rosati

Stephen Levin
Innovation in Medtech, LLC/MedTech Strategist

Kevin Keenahan
Tissue Analytics, Inc.

Katharine Ku
Wilson Sonsini Goodrich & Rosati

Landon Lack
China MedConnect

Randy Lashinski
Millipede, Inc.

Stephen Levin
Innovation in Medtech LLC/The MedTech Strategist

Bruce Lichorowic
Galen Robotics, Inc.

Chris Mansi
Viz.ai

John Maroney
Alessa Therapeutics, Inc.

Jim Martucci
Baxter International, Inc.

Casey McGlynn
Wilson Sonsini Goodrich & Rosati

Carter Meyer
Scientific Health Development

Rob Mittendorff
Norwest Venture Partners (NVP)

Susan Morano
Johnson & Johnson Medical Devices

Anne Morrissey
Alydia Health

Scott Murano
Wilson Sonsini Goodrich & Rosati

John Murphy
Virtual Incision Corporation

Philip Oettinger
Wilson Sonsini Goodrich & Rosati

 

Donna Petkanics
Wilson Sonsini Goodrich & Rosati

Heather Prado
Tandem Diabetes Care, Inc.

Sunita Rajdev
University of California, San Francisco

Stephen Ralph
W. L. Gore & Associates

Trent Reutiman
Mercator MedSystems

Bill Roskopf
Stryker Neurovascular

Stanton Rowe
NXT Biomedical

Mojgan Saadat
Arrinex, Inc.

Vahid Saadat
Arrinex, Inc.

Maria Sainz
AEGEA Medical Inc.

Siddarth Satish
Gauss Surgical, Inc.

Elton Satusky
Wilson Sonsini Goodrich & Rosati

Greg B. Scott
ChinaBio Group

Jerry Stringham
Medical Technology Partners

Brandon Suh
Lunit, Inc.

Barry Taylor
Wilson Sonsini Goodrich & Rosati

Thierry Thaure
Cephea Valve Technology

Kuo Bianchini Tong
Navigant Consulting, Inc.

Pelu Tran
Ferrum Health

Leslie Trigg
Outset Medical, Inc.

Sheila Walsh Pickering
Sheila Pickering Consulting Group

Kevin Wasserstein
Neurotechnology Innovations Translator (NIT)

Gwen Watanabe
Teleflex

Christine Winoto
Medical Technology Venture Partners (MTVP)/UCSF Rosenman Institute

Karen Wong
Wilson Sonsini Goodrich & Rosati

Paul Yock
Stanford Byers Center for BioDesign

 

Speakers Biographies

 

2Michael Ackermann
CEO, Presidio Medical

Michael is the founder of Oyster Point Pharma and currently serves as the Chairman of the Board. Michael is also developing two additional early-stage healthcare ventures. He was mostly recently Vice President, Neurostimulation for Allergan, plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan in August 2015. He has experience in medical device and pharmaceutical development in both academic and industrial settings. He received a B.E. degree, magna cum laude, in biomedical engineering from Vanderbilt University; M.S. and Ph.D. degrees in biomedical engineering from Case Western Reserve University; is a graduate of the Stanford University Biodesign Fellowship; and Vision Research Fellowship at Stanford. He has numerous patents and peer-reviewed publications.


2Jason Andrew
CEO, Limelight Health

Recognizing the early trend for InsurTech innovation in late 2013, Jason co-founded Limelight Health to deliver better data integration, underwriting, quoting and sales efficiency for carriers, brokers and others in the employee benefits ecosystem. He leveraged deep industry contacts and business development skills to build a lean startup aimed at integrating employee benefits quoting with online enrollment, HCM and payroll. Limelight now has 100+ employees and works on a national basis.


2Fabien Beckers
Founder & CEO, Arterys

Fabien Beckers is the CEO and Co-Founder of Arterys, a medical imaging startup connecting practices and disciplines to build more intelligent, accessible and powerful tools for improved patient care. Fabien holds a PhD in Quantum Physics from the University of Cambridge and a Master’s in Business from Stanford University.

Since 2012, the company’s first product, Arterys Cardio AI, was the first to receive FDA clearance for a medical device combining cloud computing and deep learning. Cardio AI is a clinical solution that enables, comprehensive, quantitative and repeatable imaging of the heart and its blood flow. Just recently, the company also received FDA clearance for Oncology AI, a suite of designed to better measure and track solid tumors.

Arterys is now working on further demonstrating the power of cloud medical imaging analytics to enable big data and precision diagnostics in the areas of oncology and cardiology.


2Adam Berman
CEO & Co-Founder, TVA Medical/Alleviant Medical

Adam has enjoyed 20 years in the medical device business, focusing on developing minimally-invasive technologies and businesses in endovascular, structural heart, renal, electrophysiology and robotics. He is currently the CEO of heart failure start-up Alleviant Medical, Inc., and most recently was CEO and Co-Founder of TVA Medical, Inc. (acquired by Becton Dickinson). TVA developed a disruptive endovascular AV fistula technology for patients requiring hemodialysis, which received both FDA market authorization and favorable US reimbursement from CMS. Prior to TVA, Adam held various commercial and R&D roles at Coalescent Surgical (acquired by Medtronic), MedicalCV and Computer Motion (acquired by Intuitive Surgical). He received his BSE Magna Cum Laude in Biomedical Engineering from Rensselaer Polytechnic Institute and his MSE in Bioengineering from the University of Washington. Adam lives in Austin, TX with his wife Susannah, daughters Ella and Marlo and their super-dog Audra.


2Russ Branaghan
President, Research Collective, LLC

With over 20 years of industry experience and consulting, Dr. Russell J. Branaghan brings expertise and vision to Research Collective as our Scientific Advisor. Russ currently serves as Chair of the HFES Product Design Technical Group, is on the Editorial Board of the Journal of Human Factors, and is on the Advisory Board for Mayo Clinic’s Center for Innovation. Additionally, as a Professor of Cognitive Psychology and Human Factors (Arizona State University) and Visiting Professor (Northwestern University), Russ is committed to the advancement of knowledge in our field.


2Lucas Buchanan
CFO, Silk Road Medical

Lucas Buchanan leads finance, strategy, corporate development, business development, reimbursement, commercial operations, and IT efforts for Silk Road Medical. Prior to joining the company full time in 2012, Lucas was an investment professional with The Vertical Group, the founding investor in Silk Road, where he helped lead the company through early development and financing milestones while charting the company’s commercial strategy. Also while at The Vertical Group, Lucas led investments in Atheromed (acquired by Volcano Corporation) and Lutonix (acquired by CR Bard). Lucas has also held various leadership positions in marketing and corporate development/M&A at Impax Laboratories and Medtronic and began his career at Ernst & Young Corporate Finance LLC where he advised healthcare companies on financing and M&A transactions. Lucas holds a B.A. in Economics from Duke University and an M.B.A. in Health Care Management from The Wharton School at the University of Pennsylvania.


2David Cassak
Editor-in-Chief, MedTech Strategist

David Cassak has more than 30 years of experience in the health care industry. Prior to co-founding Innovation In Medtech, LLC, he served as Vice President, Content and Managing Director, Medical Devices for Elsevier Business Intelligence, A Reed Elsevier Company, now part of Informa Business Information, where he wrote extensively on the medical device industry for Windhover’s monthly publications, IN VIVO and START-UP. He is also a frequent speaker before various companies and industry trade groups.

Prior to joining Elsevier, Cassak worked for nearly 20 years at Windhover Information Inc., a company he founded with his partner, Roger Longman, which spun out the publications business of The Wilkerson Group, a leading management consulting firm at the time. Long known for publishing IN VIVO, widely recognized as the premier provider of business intelligence in the health care industry, Windhover launched a number of other successful publications, including START-UP: Emerging Medical Ventures, and The RPM Report: Regulation • Policy • Market Access. In 2004, Windhover acquired Medtech Insight, Inc., which published the MEDTECH INSIGHT: Medical Technology Market Intelligence newsletter. While at Windhover/EBI, David also organized and produced numerous conferences around the world, including the Investment in Innovation (In3) medical device partnering conference series, as well as such pharma-focused conferences as Pharmaceutical Strategic Alliances, Euro-Biotech and BIO-Windhover. In 2008, Windhover was acquired by Elsevier, which formed Elsevier Business Intelligence, combining the products of Windhover and F-D-C Reports, publishers of The Gray Sheet and The Pink Sheet, among other industry newsletters.


2Tony Chou
Founder, Silk Road Medical

Dr. Chou co-founded Silk Road in 2007 and served as initial CEO. He is also general partner at The Vertical Group, a healthcare focused venture capital firm. His career includes practicing as an interventional cardiologist and experience as a medical device industry executive. He previously had general management and business development responsibilities in the Abbott Vascular Division of Abbott Laboratories and last served as Division Vice President and General Manager of the vascular closure managing the FDA approval and global launch of the Perclose and Starclose products. Prior to joining Abbott, Dr. Chou was the Director of the Adult Cardiac Catheterization Laboratory at the University of California, San Francisco where he remains Associate Professor of Medicine. Dr. Chou received an MD from Case Western Reserve University and a BS in Physics and Electrical Engineering from Carnegie Mellon University.


2Andrew Cleeland
President, Fogarty Institute for Innovation (FII)

Andrew Cleeland is the President of the Fogarty Institute for Innovation (FII), a nonprofit institution located on the El Camino Hospital campus in Mountain View and focused on providing entrepreneurs working on promising new medical therapies mentorship and access to expert intellectual, physical and financial resources to propel medical concepts from initiation to application. Prior to joining FII, Mr Cleeland Cleeland worked at Medtronic following the acquisition of Twelve Inc. Prior to Twelve, he was the president and CEO of Ardian, the pioneer of renal denervation for hypertension, heart failure and other associated disorders. Medtronic acquired Ardian in 2011 in one of the largest venture-funded exits in medtech history.


2Joe Cunningham
Managing Director, Santé Ventures

Prior to founding Santé, Joe was a healthcare Venture Partner with Austin Ventures and Vice Chair of the Ascension Health Ventures investment committee. He is also the former Chief Medical Officer of the Providence Health System and Executive Director of the 300-physician Providence Health Alliance.  He has extensive management experience and is recognized nationally for his expertise in healthcare delivery systems, physician associations and compensation models. Joe serves on advisory boards for UnitedHealthcare, Health Services Corporation (Blue Cross Blue Shield), Partners Healthcare and the Innovation Board for the Cleveland Clinic. He is board certified in both Internal Medicine and Quality Assurance and Peer Review. Dr. Cunningham received his BS and MD degrees from Texas A&M University and his MBA from Baylor University.


2William Dai
Founding Partner, ShangBay Capital

William Dai has more than 20 years of experience in corporate finance, mergers and acquisitions, and capital markets in both China and the U.S. He has held senior executive roles at major U.S. multinational companies.
In those roles, William was responsible for overall execution and was held accountable to the highest ethical standards in his business dealings.

He is well-respected among financial and investment circles, and is a recognized leader in the industry.
In addition, due to his hands-on experience leading multiple large international medical device companies, he has a very in-depth knowledge of the medical device industry and its market dynamics. William Dai holds a master’s degree in business administration with an emphasis on finance from Michigan State University.


2Jeff (J.D.) Davids
Founder, SmartMoney Ventures

J.D. is one of the most accomplished startup dealmakers in the world. He has completed well over $1 Billion in financial transactions over the last 25 years. This includes raising money from Venture Capital firms, Angel investors, and Strategic Corporate Investors as well as completing IPOs and mergers and acquisitions – both from the buy side and the sell side of the deal.

J.D. has served on the management teams of 8 VC backed startups and 3 of those companies completed successful IPOs and 3 of them were acquired by large corporations. In a market where the success rate for startup companies is less than 15%, J.D.’s success rate of 75% places him squarely into an elite class of startup dealmakers that understand how to get deals done.

At this point in his career, J.D. has dedicated his life to helping thousands of entrepreneurs raise money, build great companies, and close exit events that generate huge financial returns for entrepreneurs and their investors. Companies that work closely with J.D. are able to transform from merely “good entrepreneurs” into Accomplished Dealmakers. The difference is 85% of “good entrepreneurs” simply have never been taught how to navigate the waters of fundraising and exit. J.D. helps good entrepreneurs become part of the “Elite 15%” who break out of the pack and deliver a financial return to their investors’ cash investments and to their teams for their hard work and sweat equity.


2Ron Dollens
Retired President & CEO, Guidant Corporation

Ronald W. Dollens is the retired President and Chief Executive Officer of Guidant Corporation, a Fortune 500 company acquired in 2006 in a $27 Billion transaction.
Mr. Dollens assumed the post as President and Chief Executive Officer of Guidant when the company was formed in 1994 from a split off from Eli Lilly and Company, where he held the position as President, Medical Devices and Diagnostics.

Mr. Dollens is currently Chairman of the Board, Avanos Medical, Inc., past Chair of Kinetic Concept, Inc.’s Board, and a previous Director of Abiomed Corporation and Beckman Coulter Inc.
Mr. Dollens has held the Harold Poling Chair of Business and Government, Indiana University, and is the past Chairman of the Board of Advanced Medical Technology Association (AdvaMed), and Chairman of the Healthcare Leadership Council. Additional policy involvement has included The Advisory Committee on Regulatory Reform, appointed by U.S. Health and Human Services Secretary, Tommy G. Thompson, and a member of the New York Stock Exchange Listed Company Advisory Board.

Mr. Dollens is a director of the Regenstrief Foundation, and has been a Director for the Alliance for Aging Research, the Eiteljorg Museum, a Trustee of Butler University and past Chairman of the 2003 United Way of Central Indiana. The Healthcare Business-Women’s Association recognized Mr. Dollens as “Mentor of the Year – 2003”.

Mr. Dollens had an advisory role for Duke University’s Pratt School of Engineering, Stanford Advisory Council on Interdisciplinary Biosciences, and Purdue University’s School of Pharmacy.
Mr. Dollens received his B.S. in Pharmacy and Pharmacal Sciences, Purdue University and MBA, Indiana University and has received two honorary doctorate degrees.


2James Eadie
Partner, Santé Ventures

James joined Santé Ventures in 2010.  Previously, James served in the Air Force and was the medical director and Vice-Chair of Emergency Medicine at Wilford Hall Medical Center, an academic level-one trauma center in San Antonio.  He completed two tours in Iraq as a critical care transport team chief and as the emergency department commander.  He separated honorably as a Major in 2008.  James received his MBA from the University of Texas McCombs School Of Business, his MD from Harvard Medical School, and a BS in bioengineering, Summa Cum Laude, from the University of Michigan.  He is board certified in emergency medicine and completed his residency at Massachusetts General Hospital and Brigham and Women’s Hospital.


2Lisa Earnhardt
Executive Vice President, Medical Devices, Abbott

Lisa Earnhardt serves as Executive Vice President, Medical Devices for Abbott, a $12 billion global business with 30,000 employees. Prior to her role at Abbott she served as Intersect ENT’s President and Chief Executive Officer for 11 years until June, 2019, where she led the company from early clinical stage to commercialization of several products, initial public offering, and over $100M in revenue. Prior to joining Intersect ENT, Lisa was President of Boston Scientific’s Cardiac Surgery division. Lisa has over twenty-five years of experience in healthcare, with the majority of her earlier career leading global product launches and driving adoption of new medical technologies at Boston Scientific and Guidant (acquired). Lisa began her career at APM/CSC Healthcare where she provided management consulting services to healthcare provider organizations. She serves on the board of Intersect ENT and previously served on the boards of Nevro (NYSE: NVRO) and Kensey Nash (acquired). Lisa also serves on the board of directors of the Advanced Medical Technology Association (AdvaMed). Lisa holds a B.S. in Industrial Engineering from Stanford University and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.


2Ian Edvalson
Partner, Wilson Sonsini Goodrich & Rosati

Ian Edvalson is co-leader of the technology transactions department at Wilson Sonsini Goodrich & Rosati and is a partner in the firm’s Palo Alto and San Diego offices. He advises numerous domestic and international public and private life sciences and medtech companies, with an emphasis on biopharmaceutical and biotechnology companies, in transactions related to the discovery, development, supply, and commercialization of their products and technologies. He counsels his clients with respect to the structuring and negotiating of a wide range of agreements designed to maximize the value of their assets.

Ian specializes in working with his clients on the most complex strategic alliances and joint ventures for the development and marketing of all stages of pharmaceutical and other products. In addition, he helps companies with a broad range of other transactions, including technology and asset acquisition, license, discovery, research, development (including clinical development), manufacture and supply, promotion, marketing, distribution, and services agreements.

Ian draws on more than 25 years of business and legal experience (including his time leading the corporate and business development functions at Third Wave Technologies, a public genomics company) to address the full range of issues and transactions facing life sciences and medtech companies. He works closely with his clients in setting strategic direction and structuring and negotiating mission-critical business arrangements.


2Vera Elson
Partner, Wilson Sonsini Goodrich & Rosati

Vera M. Elson is a partner and trial lawyer based in Wilson Sonsini Goodrich & Rosati’s Palo Alto office. Her practice is focused on intellectual property trials and strategic counseling for high technology clients.

She primarily handles patent cases in federal district courts across the country and proceedings before the International Trade Commission. She has extensive trial experience in high-stakes cases, including both jury trials and bench trials. Vera has also successfully litigated cases related to trade secret misappropriation, common law, and copyright claims. She has argued and won before the U.S. Court of Appeals for the Federal Circuit. She is registered to practice before the U.S. Patent and Trademark Office. Early in her career, she was an intern for the late Chief Judge Helen W. Nies of the U.S. Court of Appeals for the Federal Circuit. Prior to law school, Vera worked as an electrical engineer doing high-speed circuit design.


2Chris Eso
Vice President, Coronary and Structural Heart Strategy, Growth and Business Development,
Medtronic

Chris Eso is Vice President of Coronary and Structural Hearth (CSH) Strategy, Growth and Business Development for Medtronic. Previously, Chris held the title for Vice President of Corporate Development, specifically covering the Cardiac and Vascular Group business units, including Cardiac Rhythm and Heart Failure (CRHF), Coronary and Structure Heart (CSH), and Aortic, Peripheral Vascular and endoVenous (APV). Chris joined Medtronic in August of 2011 and has held numerous positions of increasing responsibility and scope over his tenure at Medtronic.

Chris has more than 18 years of successful professional experience, of increasing responsibilities, with the majority of his experience in a business/corporate development and strategy capacity within the pharmaceutical and medical device industries, in addition to Medtronic, including Allergan, Watson, Agilent Technologies and Peregrine Pharmaceuticals.

Chris holds an MBA from Concordia University and BA in Public Relations, Communications from California State University, Fullerton.


2Bryant Foster
VP, Human Factors & User Experience, Research Collective, LLC

As Vice President of Human Factors and User Experience for Research Collective, LLC, Bryant guides human factors efforts for medical device manufacturers, pharmaceutical companies, automakers, consumer product manufacturers, and more. Bryant has guided surgical instruments, combination products, home-use devices, and OTC products to FDA clearance or approval. Bryant’s automotive research experience includes in-vehicle infotainment systems, automated driving systems, and audio/visual navigation tools.


2Michael Friedrich
Founder & President, DistalMotion SA

Michael Friedrich joined DistalMotion as CEO in November 2014. The Company has developed a revolutionary, low cost surgical robot for laparoscopic surgery. Prior to joining DistalMotion, Mr. Friedrich was the Founder and CEO of Aimago SA, a medical device company developing cameras to noninvasively visualize skin blood flow in real time. Aimago was sold to NOVADAQ in 2014.


2Enhao Gong
CEO, Subtle Medical

Enhao Gong is the Founder and CEO of Subtle Medical. He is a serial entrepreneur with a PhD in Electrical Engineering from Stanford University. His passion and research focuses on applying AI and deep learning to improve the reconstruction, analysis and quantification of medical imaging. His work has won several awards and has been featured in numerous academic journals and clinical conferences.


2Ginger Graham
Former President & CEO, Amylin Pharmaceuticals

Ginger Graham is the former President and CEO of Amylin Pharmaceuticals, a biotech company focused on diabetes and obesity.  During her tenure the company launched two first-in-class medicines for people with diabetes.  Prior to Amylin, Ginger was Group Chairman, Office of the President for Guidant Corporation, as the company launched the world’s leading cardiac stent platform.  Ginger has received numerous awards and honors.  She was the first woman CEO named to the PhRMA Board and Executive Committee.  She serves on the boards of directors for Walgreens Boots Alliance, Genomic Health, and Clovis Oncology.  She is also a member of the Advisory Board for the BioFrontiers Institute at the University of Colorado, the Advisory Board for the Kellogg Center for Executive Women at Northwestern University, and co-chairs the Scientific Council of the University of Colorado’s Center for Women’s Health Research.  Ginger is also the Founder and Owner of Ginger and Baker, A food hub, market and event destination in Fort Collins, housed in a historic grain mill; celebrating community, history, creativity and pie.  She received a BS, with high honors, in agricultural economics from the University of Arkansas, and holds an MBA, with distinction, from Harvard University. She is an avid horsewoman, a former Miss Rodeo Arkansas, and the proud owner of 11 registered Quarter Horses.


2Paul Grand
CEO, MedTech Innovator

Paul founded and has managed MedTech Innovator since it started as program within RCT Ventures in 2013. In 2016, with the financial support of RCT and other sponsors, Paul left to run MedTech Innovator as a stand-alone company. In his previous role as Managing Director for RCT Ventures, the investment arm of Research Corporation Technologies, Inc., Paul’s focus was on medical device investments and programs to encourage innovation and commercialization of early-stage technologies at institutions like UCLA, Stanford, USC, UCSF, UCSD, CU, Utah, and UW. Prior to joining RCT, Paul founded and operated eight hightech, medical device and biotechnology companies. In the life sciences, Grand was co-founder and VP of Operations of Imagine Pharmaceuticals and co-founder and CEO of MicroSurgeon in Los Angeles.


2Joshua Gruenspecht
Of Counsel, Wilson Sonsini Goodrich & Rosati

Joshua Gruenspecht is Of Counsel in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he advises clients in the telecommunications, technology, media, and defense sectors on transactional, regulatory, and litigation matters.

Joshua routinely represents domestic businesses and foreign entities before the Committee on Foreign Investment in the United States (CFIUS), Defense Security Service (DSS), Federal Communications Commission (FCC), federal defense and intelligence agencies, state utilities commissions, and other government bodies on national security, cybersecurity, and communications matters. He has negotiated security agreements, information sharing agreements, and network and physical security plans and policies with CFIUS, DSS, the FCC, and various other federal agencies. He currently represents the National Venture Capital Association (NVCA) in connection with the rulemaking that will implement CFIUS reform legislation.

In addition, Joshua represents companies in cybersecurity-related matters, consults on cybersecurity policies and practices, and negotiates with government agencies over access to internal networks, source code, and sensitive business information. He has represented energy companies, technology companies, and online service providers before various federal agencies over cooperative information sharing and research and development agreements, including those granting governmental access to information protected pursuant to the Electronic Communications Privacy Act, the Stored Communications Act, the pen/trap statutes, sector-specific regulations, and various federal and state privacy statutes. He also has worked with a number of Fortune 500 companies in responding to congressional, federal, and state regulatory agency requests for information regarding their cybersecurity preparedness.

Prior to joining WSGR, Joshua worked at a multinational law firm based in Washington, D.C. He was previously a Cybersecurity Fellow with the Center for Democracy and Technology, as well as an engineer working on network security research and development for the federal government and BBN Technologies, focusing on device exploitation and computer network exploitation.


2Joel Harris
Senior Director, Intellectual Property, InCube Labs

Joel has more than 30 years of experience in the medical device industry including 20 years of IP experience developing and managing patent portfolios for emerging medical device companies in the areas of cardiovascular and GI devices, implants, drug delivery, RF medical applications and others. He is currently the Senior Director of Intellectual Property at InCube Labs, a noted life science incubator led by Mir Imran. He previously worked for Wilson Sonsini Goodrich & Rosati and Kilpatrick Townsend and in house at Rita Medical Systems as their Director of Intellectual Property. In addition to extensive patent prosecution experience, he has overseen medical device IP litigation in the US and abroad.

Prior to entering into the IP field, Joel held engineering and management positions at divisions of Guidant (ACS), Abbott Laboratories, J&J and NASA working on the development of PTCA catheters, IV pumps, glucose monitors and biomedical equipment for the International Space Station. During his time at ACS, Joel worked on the development of the Rx catheter with Dr. Paul Yock.

Joel is a graduate of the Santa Clara Law School and a recipient of an Emery Scholarship and other awards for academic excellence in law school. He also has a B.S. Degree in Chemical Engineering from Northwestern University and an M.S. Degree in Bioengineering from Penn State University. He performed his graduate research on biomaterials and medical implant infection and authored several papers in the area and is an inventor on 9 US Patents in biomaterials, drug delivery and other medical technologies.


2Kristen Havranek
Associate, Wilson Sonsini Goodrich & Rosati

Kristin Havranek is an associate at Wilson Sonsini Goodrich & Rosati, where she focuses on patent prosecution and technology counseling, with an emphasis on the medical device industry. She regularly works with clients to develop their intellectual property portfolios, as well as to conduct patentability, freedom-to-operate, and patent validity analyses. She also regularly prepares and prosecutes patent applications before the U.S. Patent and Trademark Office. Kristin has worked extensively in the medical device sector, including in the areas of stents, catheter systems, medical imaging, ophthalmic devices, orthopedics, diagnostics, drug delivery devices and systems, surgical devices, and orthodontics, as well as other mechanical and electromechanical systems and equipment in and outside the medical device field.

In addition to protecting intellectual property rights, Kristin has experience with investor due diligence and financing, and has advised multiple start-up clients in connection with various rounds of financing. She also has advised clients on various aspects of licensing intellectual property.

Kristin joined the firm with nearly a decade of experience as an engineer in the medical device industry. Prior to attending law school, she was a senior engineer for Guidant Corporation in their stent cardiovascular and peripheral vascular divisions, developing combination drug-device products and self-expanding stent platforms. Before joining Guidant, Kristin was a product and process validation engineer for McGhan Medical (now INAMED Aesthetics) and worked for Genzyme Biotherapeutics as a quality analyst.


2Matt Heim
VP Sales, Qventus, Inc.

Matt Heim is Vice President, Sales for Qventus. Qventus provides a comprehensive “system of action” that enables hospitals and health systems to optimize patient flow. Incorporating modern principles of behavioral, management, and data science, the Qventus platform allows healthcare organizations to transform their operations by identifying bottlenecks before they occur, orchestrating actions among frontline teams, and managing ongoing performance.

Prior to Qventus, Matt has spent 15+ years leading sales for disruptive healthcare commercial organizations, inclusive of Datascope, Intuitive Surgical, and Medtronic. Matt believes in building teams with emotional intelligence, behavioral selling skills, and creating an environment of high accountability. Through this philosophy, Matt has been able to been able to create reproducibility and scalability in his selling organizations, enabling growth from the startup phase through to full market penetration.

One of the key highlights of Matt’s career was the work that he did with RF Surgical. Matt joined RF Surgical, a Carlsbad startup, in January of 2014. Matt rebuilt the sales team, changed the sales culture and was able to take annual recurring revenue from $10M to $50M in 18 months. This resulted in the sales of the business to Medtronic for $250M.

Matt currently resides in the greater Seattle area with his wife and three children.


2James Heslin
Partner, Wilson Sonsini Goodrich & Rosati

For more than 20 years, James Heslin has focused on helping medical device companies protect and enforce their domestic and international intellectual property rights, as well as advising venture capitalists who invest in medical technology companies. Jim’s medical and surgical device clients span a broad array of technologies, including angioplasty, atherectomy, stent delivery, arthroscopic treatments, suturing devices, ultrasound imaging and therapy, gynecological devices, minimally invasive surgical equipment, implantable hearing aids, drug delivery systems, orthodontics, orthopedics, and diagnostics.

In addition, Jim has extensive experience in investor due diligence, portfolio evaluation, licensing matters, and the preparation of patent validity and infringement opinions. He also counsels clients regarding in-house intellectual property protection programs.

Prior to joining the firm, Jim was the founder and leader of the medical device technology patent group at Townsend and Townsend and Crew (now Kilpatrick Townsend). He also served as general counsel for Align Technology.

Jim currently serves as a member of the firm’s Policy Committee.


2Steve Hochberg
Partner, Deerfield Ventures

As a Partner on the Private Transactions team at Deerfield, Steve joined Deerfield in 2013 to work on structured transactions in Deerfield’s Private Design Funds. Steve has been a founder and manager of healthcare companies for more than 20 years. Since 2004, Steve has managed Ascent Biomedical Ventures, a leading venture capital firm he co-founded focused on early stage investment and development of biomedical companies. Since 2011, Steve has been the Chairman of the Board of Continuum Health Partners until its merger with Mount Sinai in 2013, where he is the Senior Vice Chairman of the Mount Sinai Health System, a non-profit healthcare integrated delivery system in New York City with over $5 Billion in annual revenues. He graduated from the University of Michigan and earned his M.B.A. from Harvard Business School.


2David Hoffmeister
Partner, Wilson Sonsini Goodrich & Rosati

David Hoffmeister is a partner at Wilson Sonsini Goodrich & Rosati, where he plays a major leadership role in the firm’s drug and device regulatory and healthcare law practice. David was named as one of the “25 Leading Biotech Attorneys” in California in 2011 by the Daily Journal, and is recognized as one of the leading food and drug regulatory lawyers in the country.

David brings more than 25 years of experience in drug and device regulatory and healthcare law to the firm. He represents pharmaceutical, biotechnology, medical device, diagnostic, and dietary supplement clients, advising them on a variety of regulatory and healthcare issues, such as strategies for obtaining FDA product approvals and clearances, recalls, labeling, and claim support for advertising and promotional materials. He has also conducted numerous internal investigations for pharmaceutical and medical device companies involving fraud and abuse, advertising and promotional practices, and clinical research practices.

Before joining Wilson Sonsini Goodrich & Rosati, David was senior counsel for drug and device law at Syntex U.S.A., Inc., where his primary focus was advising senior management on worldwide issues affecting the ability of the corporation and its affiliates to develop, manufacture, and distribute pharmaceutical, device, diagnostic, and over-the-counter drugs in compliance with the Federal Food, Drug, and Cosmetics Act, as well as implementing regulations and applicable state and federal healthcare laws.


2Scott Huennekens
Former President & CEO, Verb Surgical

Scott is a successful entrepreneur, executive, investor and board member in medical devices, having been involved in one of those roles in 10+ startup, growth and public companies with market valuations that have totaled over $10b and more importantly over 20 million patients that have benefited from the therapies and diagnostics of these companies. He has just completed his role as Pres & CEO of Verb Surgical, Google and J&J’s Surgical Robotics start-up to revolutionize the future of surgery. Scott joined as employee #1. The big vision is being accomplished with robotics, connectivity, a digital platform with big data AI & machine learning, advanced instrumentation and enhanced visualization. The project includes team members at Verb, Google/Verily and J&J. Previously, Scott led Volcano Corp. (NASDAQ: VOLC), as its first and only Pres & CEO, from start-up in 2002 to its IPO in 2006 and sale to Philips in 2015. Volcano 2014 revenue was > $400 million and its market capitalization peaked at nearly $2b. Prior to this, he was at Digirad Corp, a diagnostic imaging solutions provider, from 1997 to 2002, as President & CEO. Digirad went public in 2004 (NASDAQ: DRAD). He graduated Magna Cum Laude with a BS in Bus Admin from the Univ. of Southern California in 1986 and earned his MBA from the Harvard Business School in 1991. Current professional affiliations include Board Nuvasive (NASDAQ: NUVA), Board ViewRay (NASDAQ: VRAY), Board TDi Medical, Board of Advisors Peloton Ventures, Board Member and past Chairman Medical Device Manufacturer’s Association (MDMA). Past affiliations include 8 other public and or VC funded medtech and biotech company boards of which 6 have had individual exits over $300 million. Scott has also been awarded E&Y’s entrepreneur of the year award in 2010 and was recognized by Goldman Sachs in 2016, 2017, & 2018 as one of the 100 most intriguing entrepreneurs at its annual Builders & Innovators conference.


2James Huie
Partner, Wilson Sonsini Goodrich & Rosati

James Huie is a corporate and securities partner in Wilson Sonsini Goodrich & Rosati’s San Francisco office. James advises life sciences and technology companies on general corporate matters, mergers and acquisitions, initial public offerings, strategic partnerships, and private equity and debt financings. He also has extensive experience in representing venture capital firms and other investors in private equity and debt financings.

 


2Beverly Huss
President & CEO, Qool Therapeutics

Beverly Huss joined Qool Therapeutics as President and CEO in September 2013. Previously, Beverly was President and CEO of Vibrynt, Inc. a company that developed a novel minimally invasive therapeutic device for treatment of morbid obesity. Prior to this, Beverly was with Santa Clara, California-based Guidant since 1986, fulfilling a variety of executive roles within the company’s various medical device divisions. She managed the worldwide Endovascular Solutions business as President and quadrupled worldwide revenues to $150 million for the carotid and peripheral vascular business in four years.

Prior to this Beverly held several executive level positions as Vice President of Guidant’s Canada and Latin America operations, Vice President of Vascular Intervention Global Marketing and Vice President of the Stent Business Unit where she built the company’s coronary stent business, a market leader for 27 of 28 quarters with revenue growth of zero to $1 billion in three years. Earlier in her career, Beverly held engineering positions at both Honeywell Defense Systems Division and Jones and Laughlin Steel. Additionally, she served as chairman of the Silicon Valley American Heart Association and as a senior advisor to Pervasis Therapeutics, a Cambridge, MA based cell therapy company.

Beverly holds a M.S. in technology management from Pepperdine University and a B.S. in metallurgical engineering from the University of Illinois. Beverly has several patents to her credit in the cardiovascular, obesity and temperature management medical device areas. In addition to the Qool Therapeutics, Board, Beverly serves the boards of Accuray, Kalera Medical, and Madorra, and the University of Illinois Material Science and Engineering steering Committee and Biomedical Engineering Steering Committee. She previously served on the boards of Surefire Medical, Ulthera, Dade Behring, Inc., Wright Medical Inc., and Artes Medical. She is a mentor in the Stanford University Biodesign Fellowship Program. Beverly was the recipient of the 2013 University of Illinois College Of Engineering Alumni Award for distinguished leadership in the medical device industry.


2Mir Imran
Chairman & CEO, Rani Therapeutics, LLC/InCube Labs, LLC

Mir Imran founded InCube Labs to focus on his passion: creating medical solutions that change the standard of care in critical healthcare markets. After attending medical school, Mir began his career as a healthcare entrepreneur in the late 1970’s and has founded numerous game-changing companies since those early days. Over the decades, he has become one of the leading inventors and entrepreneurs in the field. Mir now holds more than 200 issued patents and is perhaps most well-known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator. As an entrepreneur, Mir has founded more than 20 life sciences companies; 15 of his companies have seen “liquidity events” (IPO/Acquisition). Mir’s expertise spans a wide range of clinical areas from interventional cardiology to chronic pain, obesity and CNS disorders. Mir actively collaborates with the nation’s top universities on research and development including Stanford, Rutgers, Johns Hopkins, UTSW, etc. Mir also founded InCube Ventures, a life sciences venture fund, where he has led investments in a range of promising ventures. Mir sits on Boards of several life sciences companies. He holds an M.S. in bioengineering and a B.S. in electrical engineering from Rutgers. He also attended CMDNJ/Rutgers Medical School.


2Tomoko Ishikura
Business Development Advisor, Nipro Corporation

Tomoko is Partner at Kicker Ventures and Business Development Advisor to Nipro. Located in the SF Bay Area, Tomoko leads business development activities at Kicker Ventures in addition to fund management focusing on digital health investment. As Business Development Advisor, she supports Nipro’s due diligence process for a variety of global investment, acquisition and partnership opportunities.

Prior to joining Nipro and Kicker Ventures, Tomoko was Business Development Manager at Avantec Vascular, a U.S. subsidiary of Nipro. Prior to Avantec, Tomoko was a consultant for Axios International in France, and PwC’s PRTM and Aqumen Biopharmaceutical in Japan. She holds an MBA from INSEAD and MS in Medicine from Kyushu University. She is a member of INSEAD angels group and AIR of HealthTech Capital angels group.


2Jim Jensen
Partner, Wilson Sonsini Goodrich & Rosati

James (Jim) Jensen is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where his practice focuses on corporate and securities law. Jim has 18 years of legal experience. During that span he has represented corporate, angel, and venture capital firms in investment transactions in the U.S. and China. He also represented start-up and emerging growth companies at all stages of development. His clients include companies across a diverse range of industries, including digital media, internet, medical devices, mobile, security, and software. Jim is also a technology entrepreneur who formed and ran several e-commerce and other internet companies.

Jim’s fund services experience has involved forming angel investment and venture capital funds, and advising fund managers about ongoing operations. His experience working on corporate matters for emerging companies has included taking the lead role in mergers, acquisitions, and other restructurings, as well as counseling clients on board management and corporate governance issues. During his legal career, Jim has been involved in more than 250 investment and exit transactions.

Prior to rejoining the firm in 2019, Jim was a partner in the Palo Alto office Perkins Coie, where he was a member of the emerging companies and venture capital practice and a leader of the investment fund formation practice. Previously, from 2005 to 2011, he served as the assistant general counsel and general counsel of the emerging markets group at VantagePoint Capital Partners in San Bruno, California, where he managed hundreds of investment transactions. From 1999 to 2005, he was a corporate and fund formation associate in WSGR’s Palo Alto office.

Before entering the legal industry, Jim served as the chief financial officer at Penta Press in Miami, where he managed accounting, finance, human resource, purchasing, sales, and customer service professionals, among other duties. Earlier in his career, he was a manager of financial operations at Nobart in Chicago.


2Kevin Keenahan
Co-Founder & CEO, Tissue Analytics, Inc.

After completing his BSc in Biomedical Engineering at Johns Hopkins University, alongside a research exchange program at Tsinghua University in Beijing, Kevin joined the Center for Bioengineering Innovation and Design at Johns Hopkins University for his MSE in Bioengineering Innovation and Design. He went on to co-found Tissue Analytics, Inc. in 2014 and has been recognized as a speaker at the GSV Pioneer Summit, CES, and the Conference of the European Wound Management Association.

Tissue Analytics is a best-in-class wound imaging and documentation solution that uses computer vision to encourage better data collection and reduce electronic medical record documentation time. The technology has changed the wound care workflow for hundreds of health institutions by giving clinicians objective and automated insights into wound depth, volume, tissue types, healing velocity, and resource management. Our EMR integrations with Epic, Cerner, and Allscripts allow data to be immediately available at the point-of-care.


2Katharine Ku
Chief Licensing Advisor, Wilson Sonsini Goodrich & Rosati

Katharine “Kathy” Ku is the chief licensing advisor in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. She is also a member of the technology transactions and the patents and innovations practice groups.

Kathy is an internationally recognized leader in the field of technology transfer. She served as the Executive Director of Stanford University’s Office of Technology Licensing (OTL) for 27 years. During that period, OTL licensed hundreds of new technologies, bringing in $1.8 billion, most of which went back to support research and education at Stanford.

Kathy also spearheaded the development and implementation of nine principles related to university technology licensing. The principles are set forth in document entitled “In the Public Interest: Nine Points to Consider in Licensing University Technology.” More than 120 institutions have adopted the principles since they were published in 2007.


2Landon Lack
President & CEO, China MedConnect

Mr. Lack is a veteran of the healthcare, medical device and high tech industry in the US and China. He has had an opportunity to work for both large public companies as well as early stage venture backed companies including; McGaw Inc. (now part of B.Braun), Boston Scientific, Ask Jeeves, SealedMedia (now part of Oracle), and Capitis Healthcare China.

Living in China full time since the end of 2006, he founded China MedConnect in early 2009 and has been leading its development and growth since.

Mr. Lack received his Bachelors of Science degree from the United States Military Academy, West Point, New York, and his MBA from the China Europe International Business School (CEIBS). He lives in Beijing with his wife and three daughters.


2Randy Lashinski
President & CEO, Millipede, Inc.

Randy Lashinski joined Millipede as President and CEO in 2013 bringing to the organization a wealth of experience in early stage company executive leadership and technology innovation in the structural heart space. Prior to Millipede, Randy was the Founder, President and CEO of Claret Medical, a percutaneous, dual-filter company for TAVI procedures. Randy led the early technology invention and established and ran the clinical trial leading to CE Mark and commercialization in Europe and early IDE discussions with the FDA. In addition to Claret, Randy co-founded and was President/CEO and later Chief Technology Officer of Direct Flow Medical, a percutaneous aortic valve company. Prior to Direct Flow, Randy served as Founding Engineer and VP of Research and Development at MitraLife, later sold to ev3, where he developed a device for the treatment of mitral regurgitation. Randy’s early cardiovascular experience included various engineering roles at Arterial Vascular Engineering (AVE) / Medtronic Vascular and Target Therapeutics. Randy received his education in Mechanical Engineering from the University of Minnesota.


2Stephen Levin
Managing Partner/Editor-in-Chief, Innovation in Medtech LLC/MedTech Strategist

Prior to co-founding Innovation In Medtech, Stephen Levin served as Editor-in-Chief of Medical Devices for Elsevier Business Intelligence, where he directed the company’s editorial coverage of the medical device industry, following Elsevier’s acquisition of Windhover Information in 2008. This included managing the device content for the following publications: IN VIVO, START-UP, MEDTECH INSIGHT, The Gray Sheet, and The Silver Sheet, along with the In3 medical device partnering conference series. Stephen joined Windhover Information in 1997, whereas Executive Editor, he specialized in covering the device industry, distribution, and legal issues. He also served as the company’s General Counsel. He also formerly was an Editor of Health Industry Today, a leading publication in the health care industry.

Prior to joining Windhover, Stephen was Senior Counsel to the US Senate Permanent Subcommittee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations including the Whitewater inquiry. Before joining the Subcommittee, he was with the Federal Election Commission (enforcement and regulatory counsel) and the Department of Justice (international criminal law)


2Bruce Lichorowic
President & CEO, Galen Robotics, Inc.

Mr. Lichorowic is a highly accomplished serial entrepreneur and chief executive in the field of high tech and medical industries. Starting off in Fortune 500 companies in high tech in Silicon Valley, Mr. Lichorowic crossed into the medical field and now leverages twenty-five years of expertise in big data, machine learning, AR & VR and surgical robotics.

Mr. Lichorowic is currently the President & CEO of Galen Robotics, a spin out from Johns Hopkins University and is working with the Johns Hopkins University Robotics Lab to bring to market a new cooperative surgical robot to address the microsurgical markets within Neurosurgery, Otolaryngology, Cardio and Spine.

As a business expert, Mr. Lichorowic has been an invited speaker to major universities on the subjects of: entrepreneurship, venture funding, best practices, and the use of technology for innovation in medical. He’s also spoken on how to benefit from mergers by “Buying your way across the Chasm”.


2Chris Mansi
Co-Founder & CEO, Viz.ai

Dr. Chris Mansi is a Neurosurgeon and the CEO of Viz.ai, an applied AI healthcare company. He is a clinician innovator and entrepreneur. He cares about healthcare access, building and supporting great teams, transformative technologies, and improving provider experience to effect and scale better patient outcomes. Viz was the first FDA cleared AI software, creating a new device category; Computer Aided Triage. It uses deep learning to automatically analyze CT scans of the brain and immediately alert the stroke team about large vessel occlusion strokes, synchronizing care across a hospital network and saving time. The dual clinical and financial value proposition has led to rapid adoption; in the 9 months Viz has been on the market it has been adopted by over 250 hospitals across the USA.


2John Maroney
CEO, Alessa Therapeutics, Inc.

John Maroney is the CEO of Alessa Therapeutics, Inc. a pre-clinical stage company developing implantable drug delivery methods for solid organ tumors. John also serves as an advisor and mentor to CEOs. His particular focus is on development and early commercialization phases for medical technology companies. As a thought partner, sounding board and experienced CEO and venture capitalist, his clients find leverage and great value working with John.

In addition to Alessa, John currently serves on the Boards of GraftWorx, Inc., Radiant Oximetry, Inc. and Innovein, Inc. He is also an advisor to Enzo Relief.

Chief Executive Officers of development-stage medical technology opportunities look to John as a critical and trusted resource. He leverages an extensive network, deep industry understanding through experience as an operating leader and CEO and 10 years as a successful venture investor as a General Partner of Delphi Ventures to further your success and that of your company.


2Jim Martucci
Sr. Director, Technology Assessment & Scouting, Baxter International, Inc.

Jim Martucci is responsible for leading the CSO Technology Assessment Team, technology landscape process and providing connection between Tech Assessment, Business Development and Strategy functions. The Tech Landscape and Roadmap process addresses scouting and trending (i.e., identification, screening, analysis of emerging and early-stage technologies and product concepts). Extensive experience leading complex hardware and software product development programs in heavily regulated pharmaceutical and medical device environments, using systems engineering methodologies. Inventor on 30 issued patents; intellectual property process training. Recipient of 2014 Baxter Beacon Leadership Award and two Baxter Technical Achievement Awards. MedTech Innovator Judge, volunteer program reviewer for NUvention Medical program at Northwestern University and the Coulter Foundation program at University of Michigan.


2Casey McGlynn
Partner, Wilson Sonsini Goodrich & Rosati

In 1990, Casey McGlynn formed the Life Sciences Group at Wilson Sonsini Goodrich and Rosati, a nationally recognized leader in the representation of startup and emerging growth companies in the life sciences field. Casey has one of the largest practices in the country focused on Medtech, Mobile Health and Biotech companies.

Casey has formed, represented, sold and taken public many of the most important medical device companies started during the last 25 years.

Casey has extensive hands on experience in helping entrepreneurs form, build, fund and sell their companies. He has formed, participated with the boards of and invested in companies in all of the major Medical Device fields. Over the last 25 years he has built close working relationships with an unparalleled list of entrepreneurs, doctors, investors, engineers, and managers in this industry. Through his portfolio of companies he has met with and negotiated with the leaders of all of the major Medtech acquirers.

Over much of his career, Casey participated in forming and managing several small funds all of which have been top quartile performers. In 2005, Casey founded Life Science Angels, an angel organization focused on investing in biotechnology and medical device companies. Since formation, LSA has invested over $30 million in more than 40 companies which have received an additional $600+ million in follow-on funding from VCs.

Casey is a member of the board of directors of the Fogarty Institute for Innovation, the Medical Device Manufacturers Association and was a founding board member of the Emerging Business Committee of BIO.


2Carter Meyer
CEO & General Partner, Scientific Health Development

Carter Meyer has been the Chief Executive Officer of SHD since its formation in February 2006, and is a General Partner of SHD II and SHD III. Prior to joining SHD, he was an attorney in private practice for over 12 years, most recently with the Dallas office of the Vinson & Elkins L.L.P. As an attorney, Mr. Meyer focused on commercial transactions with substantial experience buying, selling, financing and making investments in both public and private entities. Mr. Meyer has a B.B.A. in finance from Texas Christian University and a J.D. from St. Mary’s University School of Law. Mr. Meyer is a director of all SHD portfolio companies.


2Rob Mittendorff
Partner, Norwest Venture Partners (NVP)

Robert brings to Norwest Venture Partners more than a decade of operational and medical experience. Based in Norwest’s Palo Alto office, Robert focuses on investing capital in venture and growth opportunities in the healthcare sector, including digital health and healthcare IT, technology enabled healthcare services, medical devices, diagnostics, and specialty pharma. He currently serves on the boards of Impel NeuroPharma, Qventus, Silk Road Medical, TigerConnect, and VisitPay, and is a board observer at Talkspace. He was a board member at iCardiac (acquired by ERT) and Telcare (acquired by BioTelemetry), and was a board observer at Crossover Health. Robert was involved with the initial investments in Misfit Wearables (acquired by Fossil) and Health Catalyst. He has also been involved in Norwest’s follow-on investment in Basis (acquired by Intel). Robert was a previous board observer at Intersect ENT (Nasdaq: XENT), and iRhythm Technologies (Nasdaq: IRTC). Robert is co-chair of the Digital Healthcare Innovation Summit and is a member of the Council of Leadership Fellows at Johns Hopkins.

Prior to Norwest, Robert was the Vice President of Marketing and Business Development at Hansen Medical Inc. (Nasdaq: HNSN). During his tenure, he launched multiple products, including the Magellan and Sensei X robotic systems, and was involved in leading products from concept to first commercial shipment. As a corporate officer, Robert also led the Company’s partnerships with GE, Siemens, Philips and St. Jude Medical and executed transactions totaling over $100M. He created the Scientific Advisory Board and participated in two public financings.

Prior to Hansen Medical, Robert worked in the device, pharmaceutical and biotech industries with experience at a number of companies, working in strategic, business development and marketing capacities.

Robert is also a board certified emergency physician who completed his residency training at Stanford. Robert received his M.D. from Harvard Medical School and his M.B.A. from Harvard Business School. He received his B.S. in biomedical engineering from Johns Hopkins University where he played on the soccer team. He has completed fellowships under the Howard Hughes Medical Institute (neuroscience), MIT Sloan School of Management, and Harvard Business School.


2Susan Morano
VP Business Development, Johnson & Johnson Medical Devices

As Vice President of Business Development and a member of the Medical Devices Group Operating Committee, Susan has responsibility for licensing, acquisitions and divestitures for the Medical Devices Group.

Susan joined Johnson & Johnson as a college recruit in the Finance organization. During her tenure in the Corporation, she transitioned through a number of positions with increasing responsibility through six operating companies, primarily within Finance and Business Development. Susan has been involved in a number of significant transactions within Medical Devices.

Ms. Morano received her BS in accounting from Villanova University and an MBA from Columbia University.


2Anne Morrissey
CEO, Alydia Health

Anne Ballinger Morrissey, CEO, leads the team at Alydia Health with a focus on building a profitable and sustainable company that will have lasting impact. Anne brings over 20 years of successful early stage experience including co-founding Vivant Medical (Minimally Invasive Lumpectomy) and Ucan Products (Sustainable Consumer Products). Her passion is commercializing products that make a difference. Anne has directed the successful turnaround of core businesses (GSI/TYCO), the creation of new businesses, and fundraising and strategic direction for many startups. She holds several patents.


2Scott Murano
Partner, Wilson Sonsini Goodrich & Rosati

Scott Murano is a corporate and securities partner in Wilson Sonsini Goodrich & Rosati’s Palo Alto and San Francisco offices. Scott advises companies on general corporate matters, including formation and operation, corporate governance, intellectual property and licensing, and employment-related matters. He also has assisted companies in numerous capital raising transactions, including early- and later-stage venture capital financings, debt financings, and public offerings. In addition, Scott advises companies on transactional matters and has worked on a number of merger and acquisition transactions, including public and private company mergers and acquisitions and joint ventures. Scott’s experience with venture capital financings and public offerings includes representation of venture capital firms.


2John Murphy
CEO, Virtual Incision Corporation

A global medical technology and health sciences executive, John Murphy has held leadership roles in large public companies, middle-market private equity businesses, and venture capital environments over the past 20 years. He holds graduate and undergraduate degrees in computer science and a MBA in international finance.


2Philip Oettinger
Partner, Wilson Sonsini Goodrich & Rosati

Philip Oettinger is a partner in the life sciences practice at Wilson Sonsini Goodrich & Rosati, where he focuses primarily on medical device, biotechnology, pharmaceutical, diagnostic, and digital health companies. His practice involves assisting private and public companies with corporate governance, initial public offerings, mergers and acquisitions, public company reporting, and private equity and debt financings. He routinely works with incubators on structuring matters and balancing their rights with those of the companies they are forming. Philip serves as co-chair of the Finance Committee and a member of the Compensation Committee.

From 1995 until 2000, Philip was with the Securities and Exchange Commission in Washington, D.C., where he inspected stock exchanges, worked on corporate finance matters, led enforcement investigations, and served as special counsel to Commissioner Laura S. Unger.


2Donna Petkanics
Partner, Wilson Sonsini Goodrich & Rosati

Donna Petkanics is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. Her law practice focuses on the representation of growth companies, with a particular emphasis on corporate and securities issues. She represents both privately held and public companies across a broad range of industries, including telecommunications, Internet infrastructure, networking, life sciences, computer software and hardware, clean technology and energy, and electronics. She has experience representing companies in many types of corporate transactions, including mergers and acquisitions, initial public offerings, and joint ventures. She also counsels clients who are starting new businesses with respect to general corporate matters and protection of their intellectual property.

During her tenure at the firm, Donna has served in a number of management positions, including managing director 2000 to 2006; member of the firm’s board of directors and Policy Committee; chair of the Compensation Committee; and co-chair of the Hiring Committee and Nominating Committee. She served on the board of directors of the Wilson Sonsini Goodrich & Rosati Foundation from 2000 to 2010.

Prior to attending law school, Donna was a staff economist in the Executive Office of the President during Jimmy Carter’s administration and also worked for the House of Representatives. She began practicing at Wilson Sonsini Goodrich & Rosati in 1985.


2Heather Prado
Intellectual Property Counsel, Tandem Diabetes Care, Inc.

Heather Prado is Corporate Counsel, Intellectual Property at Tandem Diabetes Care, Inc. Heather is responsible for developing and executing the global strategy relating to IP acquisition, IP portfolio development and enforcement, IP risk management, and IP due diligence for strategic partnerships and corporate investments. Prior to joining Tandem Diabetes Care, Heather was Director of Intellectual Property at NuVasive, Inc. where she led the IP efforts for the Integrated Operative Solutions (IOS) business unit including counseling in all patent, trademark, copyright, and trade secret matters for the company’s computer-assisted surgery technologies.


2Sunita Rajdev
Senior Associate Director, Innovation Ventures, Office of Technology Management, University of California, San Francisco

Sunita Rajdev joined UCSF’s Technology Management group in 2002 and is currently the Senior Associate Director of Licensing. Last year, the office received over 240 new invention disclosures, secured 195 new patents and executed 82 new license agreements that generated $35.9 million in revenue. Sunita works closely with UCSF researchers to develop strategies for protecting and commercializing a broad spectrum of intellectual property and over the years has assisted with formation of several startups. She frequently negotiates complex IP terms in collaboration and sponsored research agreements and has played a lead role in structuring several strategic alliance agreements with industry partners. After receiving an M.S. in Pharmacology from the All India Institute of Medical Sciences, New Delhi, Sunita worked in the Indian pharmaceutical Industry for a few years before moving to US to pursue Ph.D. at University of Pittsburgh followed by a postdoctoral fellowship at UCSF.


2Stephen Ralph
Innovation Marketing Leader, W. L. Gore & Associates

Stephen K. Ralph, MSc is an award-winning Executive Influencer and Marketer, with a Master in Science from University of South Wales, Chartered Marketer status, and has excelled in the Executive Education Stanford School of Business in the Biodesign Managing Innovation program as well as The Leadership Edge Executive Development Program with Alere. Stephen also holds a Six Sigma Certification.

Stephen has a passion for crafting and delivering strategic solutions that catalyze revenue growth, accelerate sales, and disrupt markets with innovative technology. By leveraging strong clinical insight, Stephen has evangelized cardiovascular, cardiac surgery, heart failure, and digital health device innovations from conception to global commercialization. Stephen is currently the Marketing Leader for Product Innovation with W. L. Gore & Associates, Inc. working collaboratively and leading cross-functional teams in identifying multimillion-dollar market opportunities for sustainable, differentiated solutions. His professional profile includes senior leadership roles at Alere, Inc., CardioMEMS, and GE Healthcare within the United States. Prior to being recruited to the US, Stephen held impactful leadership roles at both Medtronic and Baxter Healthcare. Complementing his business acumen, Stephen possesses clinical expertise as previously, he was a Clinical Physiologist with multiple healthcare systems.


2Aubrey Rankin
Co-Founder & CEO, HintMD, Inc.

Aubrey is the Co-founder and CEO of HintMD, Inc., a technology start-up based in Silicon Valley that is bringing dynamic Aesthetic Subscriptions to market through its innovative ExpertCommerce™ Platform.

Founded in 2014, the company partners with board certified physicians to create insight into gaps in patient care and offers personalized treatment plan subscription solutions to drive patient engagement, compliance and improved clinical outcomes. Its services result in significant compliance improvements, patient satisfaction and growing practice revenues and profitability.

Prior to co-founding HintMD, Aubrey was the Vice President of Asia-Pacific at ZELTIQ Aesthetics. During his time at ZELTIQ, the management team executed on one of the most successful turn-around efforts within the medical aesthetics industry. Prior to joining ZELTIQ, Aubrey held multiple management roles with Solta Medical in North America, EMEA and Asia-Pacific.

Aubrey was formerly a Director within PricewaterhouseCoopers’ M&A Advisory group during which he assisted multinational clients on M&A and Strategic Alliance projects ranging from $50M to $3.6B in value. His clients included key Fortune 500, Private Equity, and Silicon Valley Start-up companies.

He has also been active within the Silicon Valley start-up community and currently sits on the Board of FriendMedia, Inc. and Advisory Board of PB&B. Aubrey resides in the San Francisco Bay Area with his wife and two girls.


2Trent Reutiman
CEO & Director, Mercator MedSystems

Mr. Reutiman has 25 years of commercial experience in the medical device field, including leadership positions in sales and marketing, and sales management. He has significant expertise in commercializing products for minimally invasive interventional procedures, and participated in the development of many new technologies. Reutiman worked at Webster, TX-based IDEV Technologies from April 2012 to March 2014. Prior to that, from November 2006 to January 2012, he was Vice President of Sales and Marketing at San Clemente, CA-based ROX Medical, Inc. From March 2000 to December 2005 he was Vice President of Sales and Marketing at Mountain View, CA-based RITA Medical Systems. Before that Reutiman held sales management and representation positions at Guidant Corporation and Cordis Corporation. Reutiman has a bachelor of science degree in business from Colorado State University and an MBA from UC Irvine’s Paul Merage School of Business.


2Bill Roskopf
Vice President, Business Development & Strategic Planning, Stryker Neurovascular

Bill Roskopf is a medical device executive with 26 years experience in various functions, diseases and companies. Bill spent 14 years with Boston Scientific’s endoscopy division in a variety of Sales and Marketing leadership positions before transferring to Boston Scientific’s Neurovascular division in 2006 to run the Global Marketing function. Bill joined Stryker through the acquisition of BSC’s NV business in 2011 and was instrumental in both the Concentric Medical and Surpass Medical acquisitions. Currently, Bill is the VP of Business Development & Strategic Planning for Stryker Neurovascular.


2Stanton Rowe
Co-Founder & CEO, NXT Biomedical

Stanton J. Rowe is CEO of NXT Biomedical, a medical device incubator funded by Deerfield Capital. Stanton recently retired from Edwards Lifesciences where he was Chief Scientific Officer since 2008 and also served as Corporate Vice President, Advanced Technology. He joined in 2004 when Edwards acquired Percutaneous Valve Technologies, a company he helped to found in 1999 and served as President and CEO. This company developed the first transcatheter aortic valve replacement. Previously, Rowe was Corporate Vice President for Datascope and was Vice President at Johnson & Johnson’s Interventional Systems Division (JJIS) in Warren, New Jersey, responsible for the company’s coronary stent development efforts. At JJIS and the related Cordis Corporation, Rowe held a variety of positions with increasing levels of responsibility, including heading the company’s business development, advanced technology, worldwide clinical research and marketing groups. Rowe joined Cordis after previously holding several positions in product management for a number of medical device companies. He is on the board of directors of both InSeal Medical, Ltd., NeuralAnalytics, PQ Bypass. He is also on the Board of Directors for the Discovery Science Center in Orange County, Sage Hill School, as well as on the advisory boards for the engineering, business school, and biomedical engineering schools at UC Irvine. He also sits on the biomedical engineering advisory board of UC
. Rowe received a bachelor’s degree from the University of Alabama.


2Mojgan Saadat
President & Co-Founder, Arrinex, Inc.

Mojgan Saadat is an entrepreneur with many years of hands on experience. She has been a partner at Nidus Medical, LLC, a medical device incubator and angel investment entity. Nidus holds a wide variety of IP portfolios. Various innovative ideas, mostly in medical device and e-Health are evaluated at Nidus and after getting through the due diligence process, are spun off. Mojgan has been handling IP management, market analysis, financing strategy, and operations at Nidus Medical.

She is currently serving as the president of Arrinex, Inc., the most recent spin off of the incubator.
Arrinex was launched in 2013 after deep market and IP diligence and after receiving endorsement from the key opinion leaders. Mojgan has had an ongoing role in scientific and clinical due diligence, establishing Intellectual Property, strategic marketing, financing, and operations in the company.

Previously Mojgan co-founded an eHealth company called Congnitx utilizing HUD’s to help individuals with cognitive disorders. She was also engaged in a China focused company called Seris Medical developing a device for passive drainage of ascites in patients with cirrhosis.

Mojgan holds a BS in biology and a BS in computer science.


2Vahid Saadat
Co-Founder & CEO, Arrinex, Inc.

Vahid Saadat is a serial medical device entrepreneur with over 25 years of experience developing medical devices. Vahid has founded or cofounded 5 medical device startups. Currently Vahid serves as the CEO of Arrinex, Inc., which was launched in 2014. Arrinex is pioneering a procedure to provide long-term relief to chronic rhinitis sufferers through an office procedure. Prior to Arrinex, Vahid started an electrophysiology company named Voyage Medical Inc. Voyage Medical, developed the first direct endocardial visualization system called IRIS™. This device has been used to clearly visualize cardiac structures such as valves and blood vessels in a beating heart while patient is under sedation. Prior to Voyage Medical, Vahid co-founded Baxano, a spinal stenosis treatment company which later merged with Trans1. Prior to Baxano, Vahid co-founded USGI medical. USGI Medical specializes in the development of technologies to enable Incisionless Surgery. Prior to USGI, Vahid founded AngioTrax, an interventional cardiology company addressing end stage cardiac patients in 1997. Prior to AngioTrax Vahid spent several years on executive leadership positions of different medtech companies. Vahid holds a BS degree in electrical engineering and a MS degree in biomedical engineering from the University of Texas at Austin.


2Maria Sainz
President & CEO, AEGEA Medical Inc.

Maria Sainz was appointed President & CEO of AEGEA Medical in May 2018. She has over 25 years experience in commercial and leadership positions in the medtech industry. Maria has served as the President & CEO of Cardiokinetix, a medical device company pioneering a catheter-based treatment for heart failure. Prior to that, Maria was the President & CEO of Concentric Medical, Inc., a developer of minimally invasive products for the treatment of acute ischemic stroke which was acquired in 2011 by Stryker Corporation. Maria began her medtech career at Guidant Corporation where she held positions of increasing responsibility in Europe and the US. At the time of the acquisition of Guidant by Boston Scientific, Maria served as President of the Cardiac Surgery division of Guidant Corporation. Maria also serves as a Director of several public and private medical company boards. She received a M.A in Languages from the University Complutense in Madrid, Spain and a Masters in International Management from the American Graduate School of International Management.


2Siddarth Satish
Founder and CEO, Gauss Surgical, Inc.

Siddarth Satish is the Founder and CEO of Gauss Surgical, a medical technology company using computer vision and machine learning to make surgery and childbirth safer and more cost-effective. Gauss’s first application, Triton, uses the iPad to monitor blood loss from digital images of sponges and canisters, with the goal of improving obstetrical safety, reducing unnecessary transfusion, and preventing retained sponges. In his operating role, Siddarth has led the team through seven US/EU regulatory clearances (including FDA De Novo approval and raised $40 million in venture capital. Siddarth previously served as an Entrepreneur-in-Residence at StartX, Stanford University’s Startup Accelerator, and as a SIMdesign Fellow in the Department of Surgery at Stanford. Siddarth was born in India and immigrated to the United States at the age of 7. He holds a B.S. in Chemical Engineering from the University of California, Berkeley, and an M.S. in Bioengineering from the UCSF/UC Berkeley Joint Graduate Group in Bioengineering. He serves on the Technology Committee of the Anesthesia Patient Safety Foundation, and was named to the Forbes 30 Under 30 list in healthcare.


2Elton Satusky
Partner, Wilson Sonsini Goodrich & Rosati

Elton Satusky is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. He specializes in public and private corporate finance and corporate law and governance. Elton also has considerable expertise in the areas of mergers and acquisitions and venture capital.

 


2Greg B. Scott
Founder, ChinaBio Group

 

 

 


2Jerry Stringham
President, Medical Technology Partners

Mr. Stringham’s medical technology expertise began within the industry and he co-founded four medical device start-up companies. For the three decades he has been a reimbursement strategy consultant to diverse medical device, diagnostic, pharmaceutical, and investment companies. He is a regular speaker at biotechnology and medical device conferences regarding the role reimbursement plays in successfully launching new technology.


2Brandon Suh
CEO, Lunit, Inc.

Brandon studied medicine in Seoul National University and is a board-certified physician in Family Medicine, trained at Seoul National University Hospital. Prior to medical school, he studied biological sciences in KAIST and also received master¡¯s degrees in both Public Health (MPH) and Business Administration (MBA). Brandon has much experience in both basic and clinical research, having published 30+ research articles in renowned scientific journals. As CEO of Lunit, his vision is to lead the company to prolong survival and reduce medical cost by making data-driven biomarkers standard of care.


2Barry Taylor
Partner, Wilson Sonsini Goodrich & Rosati

Barry Taylor is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati with 35 years of experience as a corporate and securities attorney and investment professional.

From 2000 to 2010, Barry was a managing director in the technology, media, and telecom group of Warburg Pincus, a global private equity firm. He served as the head of the firm’s Silicon Valley office from 2000 to 2008. While at Warburg, Barry worked on investments in the United States, India, and China, and represented the firm on the boards of six portfolio companies.

Prior to joining Warburg Pincus, Barry was a senior corporate and securities partner at Wilson Sonsini Goodrich & Rosati for more than 16 years. During this time, he worked on numerous public financings as both issuers’ and underwriters’ counsel, and served as public securities counsel on disclosure, reporting, and proxy matters. This included representing 28 companies on their initial public offerings and underwriters on 40 initial public offerings. He also represented companies and investors in numerous private financings of preferred stock, convertible debt, and bridge loans with warrants. In addition, Barry negotiated and structured merger and acquisition transactions for both public and private companies. His clients included companies in a variety of sectors, including software, clean technology, healthcare, biotechnology, Internet, communications, and semiconductors.

Earlier in his career, Barry practiced with Pillsbury Madison & Sutro (now Pillsbury Winthrop Shaw Pittman) from 1975 to 1984, first as a litigator and then as a corporate and securities attorney.


2Thierry Thaure
Co-Founder and CEO, Cephea Valve Technology

Mr. Thaure is a senior executive with 30 years experience with medical devices as an entrepreneur and Chief Executive Officer. He demonstrated success in building businesses with disruptive technologies and driving their market expansion. Mr. Thaure played a key role in companies such as Origin MedSystems, Intuitive Surgical, Accuray, and EndoGastric Solutions. He has extensive experience in cardiac surgery and the early phase of angioplasty. Mr. Thaure has a BS in Biomedical Engineering from Duke University and an MBA from Kellogg’s Graduate School of Business.


2Kuo Bianchini Tong
Managing Director, Navigant Consulting, Inc.

Kuo Bianchini Tong is a Managing Director in the Life Science Practice of Navigant. He joined the firm in November of 2017 to lead up a team dedicated to market access engagements.

Kuo works with commercial stage companies to develop comprehensive market access strategies and is known for his work with disruptive technologies that have unique form factors, novel routes of delivery, policy and market access challenges, across all settings of care. Kuo also works with companies in earlier stages of development to raise funds and ensuring that product R&D and clinical activities align and support optimal pricing, reimbursement, and market access.

Prior to joining Navigant, Kuo was the CEO of Quorum Consulting, Inc. headquartered in San Francisco, CA for 21 years. During that time, Quorum was a leading firm representing clients with the Centers for Medicare & Medicaid Services (CMS); BCBS, commercial and managed care plans; and other payers and health care delivery systems in solving policy and market access issues. Prior to founding Quorum, Kuo was a Senior Associate at Health Technology Associates (now known as Covance) located in Washington, DC. Prior to entering the consulting field, Kuo as active in clinical and health services research at the University of Pennsylvania School of Medicine and the University of California, Los Angeles Neuropsychiatric Institute.

Kuo received his master’s degree from the Johns Hopkins University and his bachelor’s degree from the University of Pennsylvania (C’89).


2Pelu Tran
CEO, Ferrum Health

Mr. Pelu Tran, M.D., serves as Chief Product Officer of Augmedix, Inc. and served as its Head of Sales, Marketing, Medical Affairs. Mr. Tran has previously worked at Integra LifeSciences, Relievant Medsystems, and Science Futures. He has a MD from Stanford University and BS in Mechanical Engineering from Stanford University.


2Leslie Trigg
CEO, Outset Medical, Inc.

Leslie joined Outset from Warburg Pincus where she was an Executive in Residence. Previously, she was Executive Vice President at Lutonix, a cardiovascular medical device company acquired by CR Bard. Prior to Lutonix, Leslie served as Chief Business Officer of AccessClosure, a vascular closure company acquired by Cardinal Health. Before joining AccessClosure, she was the Vice President, Marketing for FoxHollow Technologies, helping to architect the strategy and commercial infrastructure that led to a successful IPO and subsequent acquisition by ev3/Covidien. Leslie’s management experience also includes senior leadership positions at Cytyc Corporation and breast cancer diagnostics company Pro-Duct Health, Inc., which was acquired by Cytyc. She began her medical device career at Guidant Corporation. Leslie received her undergraduate degree from Northwestern University and her MBA from the Haas School of Business, UC Berkeley.


2Sheila Walsh Pickering
Sheila Pickering Consulting Group

Dr. Walsh Pickering comes from a research science background, having received her Ph.D. in Biological Sciences from Stanford University, followed by a Post Doctoral Fellowship at the University of California at San Francisco Medical Center. During her academic career she was involved in laboratory research and development, as well as the conduct of clinical trials for the approval of implantable medical devices. Following her academic career she applied her knowledge of medical devices to working with medical device companies in regulatory affairs and quality assurance and has obtained numerous FDA product approvals. She has held management positions in both large corporations and small start-up businesses, including 3M Medical and Surgical, Acuson and Molecular Devices Corporation.

For the past 15 years she has been focused on consulting for companies from a broad range of technologies, to obtain global regulatory approvals as well as implement quality management systems in compliance with FDA’s Quality System Regulation and ISO 13485. Her experience includes the successful completion of 510(k) Notifications, Investigational Device Exemptions and Premarket Approval Applications, resulting in numerous on-time approvals for global market entry. Several of these regulatory submissions have required the successful completion of clinical trials according to international Good Clinical Practices (GCP) requirements. Productive working relationships and keen negotiating skills have been central to her successful career in Regulatory Affairs.


2Kevin Wasserstein
Founder & CEO, Neurotechnology Innovations Translator (NIT)

Kevin co-founded the NIT with Dr. Rezai, after a distinguished career spanning over 20 years in venture capital and operating roles specializing in building medical device companies from concept to commercialization. Kevin brings an experienced and practiced hand to NIT, with roles spanning investment and board leadership, executive leadership, engineering, business development, and marketing. Prior to founding NIT, Kevin founded MentorCatalyst to pursue his passion for MedTech company-building and for working intimately with entrepreneurs with a craftsman-styled approach to working with startup MedTech teams, deeply engaging on a select few startup medical device companies, providing comprehensive leadership and guidance. Prior to NIT and MentorCatalyst, Kevin spent eleven years as a Managing Director at Versant Ventures where he focused on investing in and building early stage medical device companies, and participated in the Firm’s investments in over 100 healthcare companies across 3 different investment funds, with investment allocations of over $1.1 B in capital. Kevin currently serves, or has served, in board or advisory roles with companies which include Acclarent (acquired: Johnson & Johnson), Autonomic Technologies, Cereve, Eargo, LipoSonix (acquired: Medicis), Lutonix (acquired: Bard), Microfabrica, Neoguide Systems (acquired: Intuitive Surgical), Oculeve (acquired: Allergan), Respicardia, Rox Medical, Second Sight Medical (NASDAQ: EYES), St. Francis Medical (acquired: Kyphon), and The Innovation Factory.

Kevin previously held numerous operating leadership roles, including marketing and business development at Guidant Corporation, business development at Heartstream, and engineering development and management at Hughes Aircraft Company. Kevin holds both Bachelor’s and Master’s degrees in Mechanical Engineering, specializing in product design, as well as an MBA, all from Stanford University.


2Gwen Watanabe
Vice President of Global Corporate Development, Strategy and Strategic Relationships, Teleflex

25 years of extensive global experience as a Medical Device Executive. Adept at General Management, Mergers & Acquisitions,and Corporate Strategy. Passionate about transforming businesses through growth and innovation, developing talent, optimizing resources, creating enterprise value for shareholders, developing new products and executing strategic initiatives to deliver top line growth and increase profitability.


2Christine Winoto
Partner, Medical Technology Venture Partners (MTVP) & Director, UCSF Rosenman Institute

Christine Winoto is Director of the UCSF Rosenman Institute, Deputy Director of QB3, Co-Founder and Partner at MedTech Venture Partners I LLP. Before joining UCSF, she developed business plan and marketing strategy and capital planning for Kaiser Permanente and managed business development at Genencor. In addition to consulting for startups and venture capital, she has held R&D and operations positions in medical device companies. Christine also worked in mergers and acquisitions for a European investment bank. Christine holds an MBA from Erasmus University in the Netherlands and a BS in food chemistry from the University of Wisconsin, Madison.


2Karen Wong
Senior Of Counsel, Wilson Sonsini Goodrich & Rosati

Karen serves as IP counsel to many venture-backed companies, and has worked on numerous major strategic alliance transactions, acquisitions, spin-outs, and IPOs.

Concentrating on cutting-edge biotechnology, Karen focuses her multidisciplinary practice on a combination of molecular biology, optical physics, chemical engineering, pharmacology, molecular diagnostics, and cellular physiology. She has developed technical expertise in DNA-sequencing techniques and instruments, antibody engineering and design, biofuels, drug delivery systems, gene therapies, cancer treatments, and point-of-care diagnostic tools.

Prior to practicing law, Karen conducted doctoral and postdoctoral research at Harvard and Tufts Medical School in molecular biology, cell biology, and physiology.

Karen is a co-founder and board member of BioE2E, which has built one of the largest communities of life sciences entrepreneurs in the Bay Area. A native of Sichuan, China, she is fluent in English, Mandarin, and Cantonese.


2Paul Yock
Founder & Director, Stanford Byers Center for BioDesign

Paul Yock is the Martha Meier Weiland Professor of Medicine and Mechanical Engineering (by courtesy) and Founding Co-Chair of Stanford’s Department of Bioengineering. He also holds a courtesy appointment on Operations, Information, and Technology in the Stanford School of Business.

Paul is internationally known for his work in inventing, developing, and testing new devices, including the Rapid Exchange™ balloon angioplasty system, which is now the primary system in use worldwide. He also invented a Doppler-guided access system known as the Smart Needle™ and PD-Access™. The main focus of Paul’s research program has been in the field of intravascular ultrasound. He authored the fundamental patents for mechanical intravascular ultrasound imaging and helped conduct the initial clinical trials. In 1986, he founded Cardiovascular Imaging Systems, which was acquired by Boston Scientific in 1994. Paul has also co-founded several other medical technology companies.

In his academic career, Paul has authored over 300 peer-reviewed publications, chapters and editorials, textbooks, and over 45 US patents. Recent awards include the Transcatheter Therapeutics (TCT) Career Achievement Award, the American College of Cardiology Distinguished Scientist Award, and an honorary doctorate from Amherst College. Paul is a member of the National Academy of Engineering. Current research interests of Paul’s group at Stanford focus on development and testing of catheter-based delivery systems for cardiac cell transplantation and new catheter and molecular imaging techniques for cardiology. He also founded and directs the Program in Biodesign, a unit of Stanford’s Bio-X initiative that focuses on invention and technology transfer related to biomedical engineering.